found to be largely cKit + and negative for hematopoietic lineage markers (CD45 − Lin − ), suggesting that these cells were not derived from the bone marrow (BM) but were vessel-resident vascular progenitor cells. Adventitial Sca1 + progenitor cells differentiated into smooth muscle cells expressing the mature Objective-Vascular smooth muscle cells (VSMCs) are believed to dedifferentiate and proliferate in response to vessel injury.
T he vessel wall is known to host tissue-resident stem and progenitor cells capable of forming the various cells that constitute its layers. Although the adventitia was long thought to be inert, recent studies have shown the adventitia to be a dynamic tissue playing an active role in the regulation of the vasculature. Various progenitor cell populations in the adventitia can give rise to not only vascular smooth muscle cells (VSMCs) [1] [2] [3] [4] but also endothelial cells, 2,5 pericytes, 6 and small populations of hematopoietic/myelopoietic cells. 7, 8 Indeed, it has been suggested that the adventitia may be a contributing source of long-lasting neointimal VSMCs after injury. 9 Several potential stem and progenitor cell populations have been identified as residing in the tunica media and/or adventitia, [1] [2] [3] [4] 6, [8] [9] [10] including stem cell antigen-1 + (Sca1 + ) CD45 + adventitial macrophage progenitor cells 7, 8 and Sca1 + CD45 − progenitor cells that give rise to endothelial and mesenchymal cell lineages. 5, 6 However, few studies 1, 2, 11 have identified factors that regulate the proliferation and differentiation of these vessel-resident adventitial VSMC progenitor cells.
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Hu et al 3 first identified a Sca1 + cell residing in the adventitia as a VSMC progenitor cell. When transferred to the adventitial side of irradiated vein grafts, ≤30% of neointimal cells in the graft were shown to be derived from transplanted adventitial cells. 3 When isolated and expanded in vitro, Sca1 + cells were July 2016 VSMC markers α-smooth muscle actin (ACTA2), calponin (CNN1), and smooth muscle myosin heavy chain (MYH11). 3 Passman et al 4 later identified Sonic hedgehog (Shh) signaling as critically important to the development of adventitial Sca1 + progenitor cells. Shh −/− mice had greatly reduced numbers of adventitial Sca1 + progenitor cells, suggesting that Shh signaling was critical to the development or homing of adventitial Sca1 + progenitor cells to the adventitia. 4 The differentiation of adventitial Sca1 + VSMC progenitors has been shown to be regulated by integrin/collagen-IV interactions 2 and through extracellular signal-regulated kinase/β-catenin signaling 1 after sirolimus exposure in vitro. Matrix metalloproteinase-8 11 and Stromal-cell derived factor-1 2 also seem to regulate adventitial Sca1 + VSMC progenitor cell recruitment during atherosclerosis or neointimal formation in vein grafts. However, in none of these studies were subsets of Sca1 + cells identified as being relevant to vessel remodeling in vivo, nor were their endogenous spatiotemporal patterns of abundance examined.
The hematopoietic transcription factor c-myb is known as a stem/progenitor cell regulator in multiple tissue compartments [12] [13] [14] [15] [16] [17] and has also been shown to regulate the proliferation of adult VSMCs. We have shown that c-myb regulates the differentiation of VSMCs from embryonic stem cell (ESC)-derived embryoid bodies, specifically by promoting the expansion of a Flk1 + PDGFRα − progenitor cell population in vitro. 18, 19 However, it remains unknown if such a VSMC progenitor cell exists in vivo, and if it persists into adulthood where it might contribute to vascular pathophysiology. In addition, although c-myb was shown to regulate the number of Flk1 + PDGFα − progenitor cells, the mechanism by which it regulates VSMC differentiation from progenitor cells remains unknown.
An in vivo model of c-Myb deficiency was reported by Sandberg et al, 17 where an N-ethyl-N-nitrosourea mutagenesis screen identified a mouse line with a nonlethal point mutation in c-myb. This point mutation mapped to the transactivation domain of c-Myb, resulting in defective recruitment of transcriptional coactivators (such as p300), leading to decreased activity of c-Myb. This hypomorphic (c-myb h/h ) mouse has several hematopoietic abnormalities caused by dysregulation of hematopoietic stem/progenitor cell maintenance, as well as stage-and lineage-specific blocks on differentiation. Several studies have shown that inhibiting c-myb activity reduces vessel remodeling after injury [20] [21] [22] [23] [24] [25] ; however, these studies have not been able to address if c-myb also has effects on vesselresident VSMC progenitor cells. Given the role of c-myb in other stem and progenitor cell compartments, [12] [13] [14] [15] [16] [17] as well as evidence for the role of c-myb in the differentiation of VSMCs from embryoid bodies, 18, 19 we sought to more specifically test the role of c-myb in the proliferation and differentiation of adventitial Sca1 + VSMC progenitor cells. Further defining the role of vessel-resident VSMC progenitor cells, as well as identifying specific factors involved in the proliferation, differentiation, and activity of cells recruited during the injury response may represent a novel approach to modulating vessel injury responses as diverse as neointima formation, atherosclerosis, hypertrophy, and aneurysm formation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

c-myb h/h Mice Have Defective Vessel Remodeling After Wire Denudation Injury
To examine the effect of c-myb hypomorphism on injuryinduced vessel remodeling, groups of 10-to 12-week-old male mice homozygous for the hypomorphic c-myb allele (c-myb h/h ) and their wild-type (WT) littermate controls on a C57BL/6 background were subjected to wire denudation injury of the left common carotid artery (CCA) and allowed to recover for 8, 14, or 28 days. The right CCA served as the uninjured control artery. No differences in medial or intimal area were found between WT and c-myb h/h mice at baseline ( Figure 1A ). Mice were examined 8 days post injury, a time point previously characterized as that of maximal medial proliferation. 26 No differences were found in intimal or medial remodeling between injured WT and c-myb h/h mice, suggesting that medial proliferation may not be affected in c-myb h/h mice ( Figure 1B-1D ). Given that neointimal remodeling is known to be greater at later time points, mice were also examined at 14 and 28 days post injury. At these later time points, c-myb h/h mice had decreased neointima formation at 14 days (16.7±0.3 versus 31.4±5.0×10 3 μm 3 ; N=6-7 mice per group; P<0.05) and continued to have decreased neointima area at 28 days post injury compared with WT (17.3±3.8 versus 39.6±8.5×10 3 μm 3 ; N=5-8 mice per group; P<0.0001; Figure 1E -1J). c-myb h/h mice on a FVB/N background also manifested a similar phenotype, demonstrating that the phenotype is strain independent ( Figure I in the online-only Data Supplement). Medial remodeling in c-myb h/h mice remained no different than that of WT mice ( Figure II in the online-only Data Supplement), indicating a preferential defect in cells involved in neointimal, but not medial, remodeling.
c-Myb Regulates Vessel-Intrinsic Remodeling Responses
Because c-Myb has pleiotropic roles in circulating BM-derived leukocytes and vessel-resident cells involved in the injury response, reciprocal bone marrow transplantation experiments were performed. To determine if the diminished injury response of c-myb h/h mice was vessel intrinsic or mediated by circulating BM-derived factors or cells, BM from either WT or c-myb h/h donors were transplanted into c-myb h/h recipient mice. Importantly, BM from WT donors failed to restore the injury response of c-myb h/h recipients, suggesting that the decreased neointimal response was vessel intrinsic ( Figure 2 ). In agreement with these data, there are no differences in leukocyte recruitment between WT and c-myb h/h injured vessels ( Figure 
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c-Myb Regulates Sca1 + VSMC Progenitor Cell Proliferation in Response to Vessel Injury
Because Sca1 + cells have been shown to participate in vessel remodeling, we next examined whether c-myb has a role in regulating the formation of these adventitial VSMC progenitor cells. The CCA of WT and c-myb h/h mice were found not to differ in the number of adventitial Sca1 + cells as assessed by immuonohistology ( Figure 3A and 3B; Figure V in the onlineonly Data Supplement), suggesting that c-myb may not regulate the development of Sca1 + adventitial VSMC progenitor cells. Although previous studies have relied heavily on histological identification of Sca1 + cells, this method has technical limitations for the identification and quantification of specific subpopulations of Sca1 + cells. Accordingly, we also used flow cytometry to refine the analysis of adventitial VSMC progenitor cell populations and their response to injury. Consistent with previous studies, 3, 4 we have defined Sca1 + adventitial VSMC progenitor cells as CD45 − Lineage − (Lin; CD3 − , CD31 − , CD11b − , B220 − , Nk1.1 − , and Ter119 − ) Sca1 + cells ( Figure 3C ; Figure c-myb h/h CD45 − Lin − Sca1 + cells had decreased BrdU incorporation compared with WT cells at 8 days (5.4±0.8% versus 9.1±0.6%), 14 days (2.4±0.4% versus 4.9±0.4%), and 28 days post injury (2.0±0.6% versus 4.1±0.6%; N=3-10 mice per group; 8 days: P<0.001, 14 days and 28 days: P<0.05), indicating that c-myb promotes the proliferation of CD45 − Lin − Sca1 + adventitial progenitor cells ( Figure 3F and 3G).
Expansion of Sca1 + Adventitial Cells After Injury Is Derived From Vessel-Resident Cells and Not Circulating Cells
Because Sca1 + adventitial VSMC progenitor cells could potentially arise locally or be recruited from the circulation in response to injury, we injured WT and c-myb h/h mice transplanted with eGFP + c-myb WT BM. This analysis revealed that both at baseline and at 28 days post injury, >99% of all carotid adventitial CD45 − Lin − Sca1 + cells remain host vessel derived (ie, eGFP − ; Figure 4A ), which was consistent in the aortic arch ( Figure 4B ). Excluding the possibility that incomplete or unsuccessful BM reconstitution might explain the above result, >99% of blood cells were eGFP + ( Figure 4C ).
c-Myb Specifically Regulates Sca1 + cKit + CD34 − Flk1 − Cells in Response to Vessel Injury
cKit, CD34, and Flk1 have been identified as potential additional markers of adventitial Sca1 + progenitor cells that can differentiate into VSMCs, 3 ,4 yet it is not known if one or a combination of these markers identifies VSMC progenitor cell populations that may be involved in the injury response in vivo. Thus, we next examined the expression of cKit, CD34, and Flk1 within CD45 − Lin − Sca1 + cells in the uninjured carotid as well as after vessel injury and found that few CD45 − Lin − Sca1 + cells in the uninjured carotid artery are cKit − CD34 + (0.15±0.04%) or cKit + CD34 + (0.38±0.09%) and that these proportions were not different between WT and c-myb h/h mice ( Figure 5A and 5B). Of interest, the relative abundance of CD45 − Lin − Sca1 + Flk1 + cells in carotid arteries was decreased at 14 and 28 days post injury as compared with baseline and did not differ between WT and c-myb h/h mice ( Figure VII in the online-only Data Supplement). By contrast, we found that at 8 and 14 days post injury, there is an expansion specifically of the cKit + CD34 − population, whereas cKit − CD34 + and cKit + CD34 + cells remained unchanged ( Figure 5B ) in WT mice. However, in c-myb h/h mice, the cKit + CD34 − population failed to expand to the same extent as in WT mice (10.4±0.8% versus 14.8±1.1%; N=5 mice per group; P<0.05; Figure 5A and 5B). When adventitial Sca1 + cells isolated from carotid arteries were cultured in vitro, there was decreased proliferation of c-myb h/h Sca1 + cells (6.1±1.5% versus 21.1±1.1% WT Sca1 + BrdU + cells; Figure 5C ), whereas the relative abundance of Sca1 + cells did not differ between genotypes ( Figure VIIIA in the online-only Data Supplement). It was also found that there were fewer Sca1 + cKit + cells in cultures isolated from c-myb h/h carotid arteries versus WT carotid arteries (3.1±0.7% versus 16.2±0.5%; N=3 mice per group; P<0.05; Figure 5D ). When the expression of cKit and CD34 was examined on proliferating (BrdU + ) Sca1 + cells in vitro, it was found that in both genotypes, proliferating cells were predominantly cKit + (Figure 5E ).
c-Myb Regulates the Differentiation of Adventitial Sca1 + Cells Into VSMCs
To examine whether c-myb is involved in the differentiation of Sca1 + adventitial VSMC progenitor cells, cells were isolated from WT and c-myb h/h mice and differentiated in the presence of 0.2% fetal bovine serum and 10 ng/mL transforming growth factor-β1 (TGF-β1) for 7 days. Unlike WT cells, c-myb h/h adventitial Sca1 + VSMC progenitor cells did not effectively upregulate markers of differentiated VSMCs, such as CNN1, MYH11, ACTA2, and myocardin ( Figure  6A-6C 
The Myocardin Gene Promoter Is Bound and Transcriptionally Activated by c-Myb During VSMC Differentiation
Although c-myb has been previously demonstrated to regulate ESC differentiation to VSMCs, 18, 19 the mechanism by which c-myb promotes VSMC differentiation remains unclear. When Sca1 + VSMC progenitor cells were differentiated, c-myb h/h Sca1 + VSMC progenitor cells failed to upregulate myocardin expression ( Figure 6A) . Similarly, c-myb h/h CCA have lower myocardin expression than that of WT CCA ( Figure 6D ). Adenoviral overexpression of myocardin before differentiation restored SMC gene expression in differentiated c-myb h/h adventitial Sca1 + VSMC progenitor cells ( Figure 6E ). c-Myb-dependent activation of myocardin was determined using a heterologous system by cotransfection of a myocardin promoter-luciferase construct and either a c-Myb expression or empty control vector into human embryonic kidney 293 cells. Overexpression of c-Myb resulted in activation of the myocardin promoter ( Figure 7A ). Cotransfection of hypomorphic c-Myb resulted in decreased myocardin-luciferase reporter activity ( Figure 7A) , as did the cotransfection of a distinct mutant c-Myb (mR3-3), 
Discussion
It has been established that c-myb regulates the proliferation of VSMCs and the differentiation of VSMCs from ESCderived progenitors in vitro [18] [19] [20] 29, 30 ; however, it remained unknown if c-myb has a similar role in adult vessel-resident VSMC progenitor cells in vivo. Here, we show that a mouse harboring a point-mutated c-myb has defects in vessel remodeling in response to wire denudation injury and that this is a vessel-intrinsic defect associated with defective proliferation of Sca1 + adventitial VSMC progenitor cells. Although c-myb does not seem to have a developmental role in the formation of Sca1 + adventitial VSMC progenitor cells, our data demonstrate that c-myb regulates the proliferation of CD45 − Lin − Sca1 + cells in response to wire denudation injury. Moreover, we have identified that cKit + Sca1 + progenitor cells expand in response to wire denudation injury, whereas CD34 + and Flk1 + cells do not. In vitro differentiation of c-myb h/h -derived adventitial VSMC progenitor cells failed to effectively generate mature VSMCs, demonstrating that c-myb also promotes the differentiation of adventitial progenitor cells. Finally, our data demonstrate that c-myb regulates VSMC differentiation through the binding and transcriptional regulation of the myocardin gene. These results together demonstrate a role for c-myb in regulating the proliferation and differentiation of an adult vessel-resident VSMC progenitor cell.
c-Myb Regulates Sca1 + Progenitor Cells in Response to Injury
In this study, we have established that adventitial Sca1 + progenitor cell development does not seem to be regulated by c-myb, because no differences in the number of adventitial Sca1 + cells were found by histology or flow cytometry of uninjured vessels in WT and c-myb h/h mice. However, on injury, there is a significant impairment in the ability of c-myb h/h Sca1 + progenitor cells to proliferate as compared with WT Sca1 + cells. This role for c-myb in the proliferation of Sca1 + cells is similar to its already established role in VSMC proliferation, providing evidence that c-myb regulates not only mature VSMC proliferation but also the proliferation of adult vessel-resident VSMC progenitor cells.
Sca1 + Progenitors Are Vessel Resident and Expand After Vessel Injury
Using WT and c-myb h/h mice lethally irradiated and reconstituted with eGFP + BM, we have shown that CD45 − Lin − Sca1 + cells in the carotid artery and aorta are not BM derived. In response to wire denudation injury, the Sca1 + cell population proliferates; when mice reconstituted with eGFP + BM were injured, the CD45 − Lin − Sca1 + cells remained eGFP − , confirming that Sca1 + adventitial progenitor cells are not BM-derived cells at baseline or in response to injury but are in fact adult vessel-resident progenitor cells. In addition, leukocyte recruitment is not impaired in c-myb h/h injured vessels, suggesting that c-myb does not regulate inflammatory cell recruitment in response to vessel injury. Although reconstitution of c-myb h/h mice with WT BM was not sufficient to restore their injury response, the reciprocal experiment in which WT mice were reconstituted with c-myb h/h BM revealed that c-myb h/h BM had a protective effect on neointimal remodeling, demonstrating the complexity of neointimal remodeling. Given the various hematopoietic abnormalities caused by c-myb hypomorphism, 17 precise elucidation of which BM-derived cell populations mediate the latter phenotype would require complex stage-and lineage-specific transplantation or genetic ablation models beyond the scope of this study. Moreover, the contribution of BM-derived protection to the decreased vessel remodeling of c-myb h/h mice, although noteworthy, is overshadowed in the context of wire denudation injury, given that WT BM is insufficient to restore a normal injury response to c-myb h/h mice. Taken together, these results show that although c-myb h/h BM-derived cells also confer some level of protection from neointimal remodeling, the defect in vessel remodeling is intrinsic to the c-myb h/h vessel-resident cells. Consistent with this observation, when TGF-β1 expression was examined in WT and c-myb h/h arteries post injury, there was no difference in TGF-β1 mRNA levels. Rather, Sca1 + cells isolated from c-myb h/h mice manifest defective responses to TGF-β1 treatment, suggesting that the observed phenotype was independent of circulating or secreted factors. A limitation of this study is that other cell compartments such as endothelial cells, pericytes, and BM-derived cells from c-myb h/h mice may also harbor uncharacterized defects; however, our bone marrow transplantation and in vitro experiments suggest that the effects observed in Sca1 + cells are cell intrinsic and not dependent on other cell types.
c-Myb Specifically Regulates the Expansion of cKit + Sca1 + Cells
We have shown previously that c-myb has a role in regulating ESC differentiation into VSMCs through the expansion of a subset of hemogenic VSMC progenitor cells that are Flk1 + . 18 However, it was not known if c-myb has such a role in adult vessel-resident progenitor cells in vivo. On the basis of our earlier work, we hypothesized that an Flk1 + progenitor might persist within the Sca1 + adventitial progenitor cell population, and this adult Sca1 + Flk1 + cell population would be regulated by c-myb in vivo. Histological examination of mouse adventitia in a previous report suggested that adventitial Sca1 + progenitor cells are a heterogenous population expressing CD34 or Flk1; however, flow cytometric analysis identified adventitial Sca1 + cells as Lin − cKit + . 3 A separate study found that freshly isolated adventitial Sca1 + progenitor cells were cKit − CD34 + CD140b + CD45 − CD68 − 4; however, these expression data came from reverse transcription-PCR of magnetically isolated Sca1 + cells without lineage exclusion and were not validated by flow cytometry or immunostaining. In this study, a flow cytometry approach to analyze adventitial Sca1 + progenitor cell populations was used to quantitatively determine markers to identify progenitor cells relevant to vessel remodeling after injury. No baseline differences between WT and c-myb h/h Sca1 + cell population expression of cKit, CD34, and Flk1 were found. After vessel injury, although CD34 + and Flk1 + cells declined, cKit + cells expanded in response to injury in WT mice. However, in c-myb h/h mice post injury, a defect in the expansion of Sca1 + cKit + cells was identified. Consistent with these results, when adventitial Sca1 + cells were isolated from WT and c-myb h/h carotid arteries, a proliferative defect was observed specifically in c-myb h/h cKit + CD34 − Sca1 + cells. It is tempting to speculate that CD34 and Flk1 represent markers of quiescent versus activated Sca1 + VSMC progenitors and that expression of CD34 and Flk1 are downregulated by activation of Sca1 + progenitor cells. Although the baseline number of Sca1 + progenitors and CD34 + and Flk + subpopulations did not differ between WT and c-myb h/h mice, we have not excluded the possibility that the function of these progenitors remains disturbed and may also contribute to the overall vascular phenotype of this mutant mouse. Additionally, it remains unknown if there are differential responses of adventitial progenitor cells based on embryological origins or vessel size, because previous reports examined aortic arch adventitial VSMC progenitor cells, which may be of embryological origins distinct from that of carotid artery adventitial cells.
c-Myb Regulates the Differentiation of Adventitial Sca1 + VSMC Progenitor Cells
To date, there have been few reports of transcription factors that regulate the differentiation capacity of adventitial Sca1 + VSMC progenitor cells. WT adventitial Sca1 + VSMC progenitor cells differentiated into VSMCs as evidenced by expression of VSMC markers Cnn1, Acta2, Myh11, and myocardin. By contrast, c-myb h/h adventitial Sca1 + VSMC progenitor cells incompletely upregulated expression of these genes, suggesting that they are defective in their ability to differentiate into VSMCs, demonstrating the requirement for functional c-myb in the differentiation of this VSMC progenitor cell population.
c-Myb Binds the Myocardin Promoter During VSMC Differentiation
Undifferentiated Sca1 + adventitial VSMC progenitor cells were shown to be primed for VSMC differentiation through the coexpression of serum response factor and myocardin, while also having high expression of transcriptional corepressors of VSMC differentiation Msh homeobox 1, Kruppel-like factor 4, and Forkhead box protein O4. 4 In WT adventitial Sca1 + cells, the expression of Msh homeobox 1, Kruppel-like factor 4, and Forkhead box protein O4 decreased over time because cells differentiated, whereas serum response factor and myocardin were upregulated. 4 Because myocardin expression was lower in c-myb h/h carotid arteries at baseline and after injury and incompletely upregulated in response to TGF-β1 in vitro in c-myb h/h adventitial Sca1 + VSMC progenitor cells, we hypothesized that c-myb regulates VSMC differentiation of Sca1 + smooth muscle progenitor cells via transcriptional control over myocardin. 19 Adenoviral overexpression of myocardin rescued the expression of SMC genes in differentiated c-myb h/h Sca1 + VSMC progenitor cells. Although these data demonstrate that c-Myb regulates VSMC differentiation at least partly through myocardin, we have not excluded the possibility that additional mechanisms may also be regulated by c-myb.
In a heterologous system, c-Myb overexpression was sufficient to activate a myocardin promoter-luciferase construct, further demonstrating that c-Myb activates myocardin expression. Consistent with our observations from c-myb h/h Sca1 + VSMC progenitor cells, transfection of our system with hypomorphic c-Myb did not activate the myocardin promoter reporter construct as effectively as WT c-Myb. Importantly, a second c-Myb mutant (mR3-3), previously shown to have defective transactivation of c-Myb target genes, 27 also failed to activate a myocardin reporter. Taken together, these data demonstrate that c-Myb is critical for the activation of myocardin expression. Interestingly, the promyogenic activity of myocardin is enhanced by p300, 31 a histone acetyltransferase known to have defective interaction with the mutant-c-Myb expressed in c-myb h/h mice. 17 Given the specific defect in the transactivation domain of the c-myb hypomorph studied, it is also likely that interaction of c-myb with other transcriptional coactivators is necessary for efficient activation of the myocardin promoter and subsequent differentiation of adventitial Sca1 + VSMC progenitors into VSMCs.
Chromatin immunoprecipitation with anti-c-Myb in Sca1 + VSMC progenitor cells demonstrated binding of c-Myb to the myocardin promoter in 2 regions of the core promoter. Importantly, c-Myb binding to the myocardin promoter could not be detected in undifferentiated cells, demonstrating that there is dynamic and direct regulation of myocardin transcription by c-Myb during differentiation of Sca1 + adventitial VSMC progenitor cells into VSMCs. Through site-directed mutagenesis, it was determined that MBS2 was not as critical for c-Myb-induced promoter activity, whereas mutagenesis of MBS1 and MBS8 significantly decreased c-Myb-induced myocardin promoter activity. Interestingly, the mutation created in MBS3 (CAGCGGTC changed to CccgGGTC) generated a myocardin-luciferase construct with 8.0×10 5 -fold higher activity than the WT myocardin promoter, suggesting either inadvertent creation of a binding site for another potent transcriptional activator or, more likely, loss of an inhibitory element in the myocardin promoter. This is the direct mechanistic demonstration of how c-myb regulates the differentiation of progenitor cells into VSMCs and provides insight into how c-myb regulates the expression of multiple VSMC genes simultaneously.
It had been widely accepted that VSMC-like cells involved in the neointimal injury response are derived from the phenotypic modulation of contractile medial VSMCs into proliferative synthetic VSMCs. [32] [33] [34] However, emerging evidence now suggests that local progenitor populations residing in various compartments of the vessel wall may in fact be a contributing source of synthetic VSMCs in response to injury. 2,3,6,9 Through lineage-tagging experiments, it has been suggested that neointimal VSMCs may also be generated in part by the proliferation and differentiation of multipotent vessel-resident stem and progenitor cells. 9 We now demonstrate that c-myb regulates the proliferation and differentiation of an adventitial Sca1 + VSMC progenitor cell. A limitation of this study is that we have yet to directly examine the relative contribution of the adventitial Sca1 + VSMC progenitor cell to neointimal remodeling. In future studies, progenitor cell recruitment will need to be demonstrated with coordinated spatiotemporal expression of several inducible lineage markers to conclusively delineate the contribution from heterogeneous populations of adventitial progenitor cells to vessel remodeling. Although this study cannot clarify the relative contribution of adventitial progenitor cells to vessel remodeling, the results do identify the expansion of a CD45 − Lin − Sca1 + cKit + progenitor cell population in response to vessel injury, informing specific markers necessary to define a relevant cell population in future studies.
Although c-myb has been shown to regulate VSMC differentiation from ESCs in vitro, we have now demonstrated that c-myb also plays a pathophysiological role in the regulation of adult vessel progenitor cells that participate in neointimal remodeling. By regulating both the proliferation and myocardin-dependent differentiation of adventitial VSMC progenitor cells, c-myb has a profound role in the functional capacity of adventitial VSMC progenitor cells and thus may represent a novel approach to modulating injury responses of vessels. Although current therapies for many vascular diseases include systemic administration of therapeutic factors, understanding the functional role of local vessel-resident stem and progenitor cells and the factors that regulate their activity may represent novel refinements to the therapeutic success of vascular interventions.
